<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <id>https://recalls.watch/feed/substance-ranolazine.xml</id>
  <title>Recalls Watch: Ranolazine</title>
  <link rel="self" href="https://recalls.watch/feed/substance-ranolazine.xml"/>
  <link href="https://recalls.watch/alerts/"/>
  <updated>2026-10-07T00:00:00Z</updated>
  <entry>
    <id>https://recalls.watch/recall/fda/99893/</id>
    <title>Ajanta Pharma USA Inc: Ranolazine Extended-Release Tablets</title>
    <link href="https://recalls.watch/recall/fda/99893/"/>
    <updated>2026-10-07T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Failed Dissolution Specifications: below specification</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/96474/</id>
    <title>Glenmark Pharmaceuticals Inc., USA: Fenofibrate Capsules 67 mg and 38 more</title>
    <link href="https://recalls.watch/recall/fda/96474/"/>
    <updated>2025-04-16T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/93263/</id>
    <title>Glenmark Pharmaceuticals Inc., USA: Ranolazine Extended-Release Tablets 500mg</title>
    <link href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=93263"/>
    <updated>2023-11-15T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Failed Dissolution Specifications: Out of specification for dissolution.</summary>
  </entry>
</feed>
